Jennison Associates LLC lowered its stake in shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) by 4.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,396,667 shares of the biotechnology company’s stock after selling 57,862 shares during the period. Jennison Associates LLC owned about 10.38% of Aeglea BioTherapeutics worth $5,363,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new position in shares of Aeglea BioTherapeutics during the first quarter valued at $157,000. Renaissance Technologies LLC purchased a new position in shares of Aeglea BioTherapeutics during the first quarter valued at $270,000. Finally, Norges Bank purchased a new position in shares of Aeglea BioTherapeutics during the fourth quarter valued at $275,000. 48.10% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Aeglea BioTherapeutics, Inc. (NASDAQ AGLE) opened at 3.30 on Tuesday. The firm’s 50-day moving average is $3.32 and its 200-day moving average is $5.13. Aeglea BioTherapeutics, Inc. has a 52 week low of $2.81 and a 52 week high of $10.34. The stock’s market capitalization is $54.29 million.

TRADEMARK VIOLATION NOTICE: This article was first reported by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/jennison-associates-llc-sells-57862-shares-of-aeglea-biotherapeutics-inc-agle/1529156.html.

Several brokerages have recently weighed in on AGLE. TheStreet cut shares of Aeglea BioTherapeutics from a “c-” rating to a “d+” rating in a research report on Friday, May 26th. ValuEngine raised shares of Aeglea BioTherapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Zacks Investment Research raised shares of Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a research report on Thursday, August 3rd.

Aeglea BioTherapeutics Company Profile

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Institutional Ownership by Quarter for Aeglea BioTherapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.